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ABSTRACT
OBJECTIVES This study sought to better understand the discrepant results of 2 trials of serelaxin on acute heart failure
(AHF) and short-term mortality after AHF by analyzing causes of death of patients in the RELAX-AHF-2 (Efficacy, Safety
and Tolerability of Serelaxin When Added to Standard Therapy in AHF-2) trial.
BACKGROUND Patients with AHF continue to suffer significant short-term mortality, but limited systematic analyses
of causes of death in this patient population are available.
METHODS Adjudicated cause of death of patients in RELAX-AHF-2, a randomized, double-blind, placebo-controlled
trial of serelaxin in patients with AHF across the spectrum of ejection fraction (EF), was analyzed.
RESULTS By 180 days of follow-up, 11.5% of patients in RELAX-AHF-2 died, primarily due to heart failure (HF) (38% of
all deaths). Unlike RELAX-AHF, there was no apparent effect of treatment with serelaxin on any category of cause of
death. Older patients ($75 years) had higher rates of mortality (14.2% vs. 8.8%) and noncardiovascular (CV) death (27%
vs. 19%) compared to younger patients. Patients with preserved EF ($50%) had lower rates of HF-related mortality
(30% vs. 40%) but higher non-CV mortality (36% vs. 20%) compared to patients with reduced EF.
CONCLUSIONS Despite previous data suggesting benefit of serelaxin in AHF, treatment with serelaxin was not found
to improve overall mortality or have an effect on any category of cause of death in RELAX-AHF-2. Careful adjudication of
events in the serelaxin trials showed that older patients and those with preserved EF had fewer deaths from HF or sudden
death and more deaths from other CV causes and from noncardiac causes. (Efficacy, Safety and Tolerability of Serelaxin
When Added to Standard Therapy in AHF [RELAX-AHF-2]; NCT01870778) (J Am Coll Cardiol HF 2020;8:999–1008)
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H ospitalization for acute heart fail-ure (AHF) is associated with signif-icant short- and long-term
morbidity and mortality, and to date no spe-
cific therapy has been developed to improve
these outcomes. Given that many patients
with heart failure (HF) are older and have a
high burden of comorbidities, the period af-
ter hospitalization is marked by a variety of
competing risks for both cardiovascular (CV)
and non-CV events. Improved understanding
of the specific causes of mortality after AHF
may help identify strategies for better addressing
poor outcomes in these patients.
The RELAX-AHF (Efficacy, Safety and Tolerability
of Serelaxin When Added to Standard Therapy in
AHF) and RELAX-AHF-2 studies were global, phase
III, randomized clinical trials evaluating the safety
and efficacy of serelaxin, a recombinant form of
human relaxin-2, in patients hospitalized with AHF
(1,2). The hormone relaxin contributes to many of
the CV adaptations of pregnancy, including
decreased systemic vascular resistance, increased
renal blood flow, and augmented cardiac output
(3,4). Additional pleotropic properties possibly
include anti-inflammatory, angiogenic, anti-
ischemic, and antifibrotic effects (4,5). RELAX-AHF
randomized 1,161 patients with AHF and demon-
strated improvement in dyspnea (the primary
endpoint) as well as lower CV mortality (1). A sub-
sequent analysis of adjudicated cause of death in
these patients revealed that improved survival in
the serelaxin arm of RELAX-AHF was primarily
mediated by reduction in “other CV deaths” (which
itself was largely driven by a reduction in stroke),
with a modest reduction in sudden cardiac death
(SCD) (6).
These findings led to a larger global trial of 6,545
patients, RELAX-AHF-2, which was designed to test
the hypothesis that early administration of serelaxin
would reduce CV mortality at 180 days and worsening
HF through 5 days compared to placebo (2). Despite
the promising findings of RELAX-AHF, RELAX-AHF-2
failed to conclusively demonstrate benefits on either
of these outcomes. In the current analysis, our pri-
mary goals were to utilize data on adjudicated cause
of death from the RELAX-AHF-2 trial to (1) inform
understanding of the discrepant results of the
RELAX-AHF and RELAX-AHF-2 studies; and (2)
identify potential opportunities to better target
therapies after AHF hospitalization, especially in
previously understudied groups (e.g., the elderly and
patients with HF with preserved ejection fraction
[HFpEF]).
FIGURE 1 Categorical Representation of Cause of Death in RELAX-AHF-2 Compared to RELAX-AHF
Comparison of causes of death between RELAX-AHF-2 and RELAX-AHF. In total, 755 of 6,545 patients (11.5%) in RELAX-AHF2 and 107 of
1,161 patients (9.2%) in RELAX-AHF died by 180 days of follow-up. Both trials had similar proportions of patients in 4 categories of death
(p ¼ 0.2370). Other cardiovascular (CV) deaths include CV deaths not attributable to heart failure (HF) or sudden cardiac death (SCD) (e.g.,
acute coronary syndrome, cerebrovascular accident, etc.). Non-CV deaths represent all other deaths (e.g., renal failure, sepsis, etc.). RELAX-
AHF ¼ Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF.
ABBR EV I A T I ON S
AND ACRONYMS
AHF = acute heart failure
CV = cardiovascular
EF = ejection fraction
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
SCD = sudden cardiac death
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METHODS
RELAX-AHF-2 was a multicenter, randomized,
double-blind, placebo-controlled, event-driven trial
that randomized patients admitted to the hospital for
AHF with symptoms of dyspnea, congestion on chest
radiography, elevation in natriuretic peptide con-
centrations, systolic blood pressure at least
125mm Hg, and mild-to-moderate renal impairment
(estimated glomerular filtration rate 25 to 75 ml/
min/1.73 m2 body surface area) to serelaxin or
matching placebo. The trial design and primary re-
sults have been previously reported (2,7). In brief,
patients who remained symptomatic after 1 dose of
intravenous furosemide (at least 40 mg or equivalent)
were eligible for randomization. Randomization
occurred within 16 h of presentation or first intrave-
nous administration of loop diuretic in a 1:1 ratio.
Patients received either serelaxin at a dose of
30 mg/kg/day or matching placebo, beginning no more
than 4 h after randomization, for up to 48 h. Serelaxin
dosing was adjusted or discontinued in response to
decreases in systolic blood pressure according to
protocol. The ethics committee at each participating
center approved the study, and patients provided
written informed consent.
The trial had 2 primary efficacy endpoints: death
from CV causes at 180 days and worsening HF
(defined as worsening signs and symptoms of HF
necessitating the addition or escalation of HF ther-
apy) at 5 days. Secondary endpoints included death
from any cause at 180 days, length of index hospital
stay, and a composite of death from CV causes or
rehospitalization for HF or renal failure at 180 days.
EVENT ADJUDICATION. A clinical events committee
blinded to treatment allocation adjudicated all deaths
and hospitalizations that occurred up to 180 days. For
each event, the committee reviewed the case report
form and all available relevant source documents
from the medical record, including hospital notes,
discharge summaries, autopsy reports, and death
certificates. Definitions of each cause of death were
previously developed by the clinical events commit-
tee and approved by the study executive committee.
Specific event definitions and the adjudication pro-
cess were generally the same in both RELAX-AHF
studies. Specific definitions used to adjudicate
deaths are summarized in Supplemental Appendix
A (1,6).
STATISTICAL ANALYSIS. Baseline characteristics are
described using appropriate descriptive statistics
(percentage, mean  SD, or median [interquartile
range] depending on the type of variable and its
distribution). Deaths were grouped into pre-defined
categories, similar to those used for the cause of
death analysis of RELAX-AHF (6). CV causes of death
included HF, SCD, and other CV death. Other CV
deaths included cerebrovascular events (ischemic,
hemorrhagic, or unknown stroke), acute coronary
syndrome, systemic or pulmonary embolism, CV
procedure complication, or presumed/unknown CV
death. The final category of non-CV deaths included
all other causes of death (e.g., sepsis, malignancy,
renal failure, etc.).
Cox proportional hazards models were used to
assess the treatment effect of serelaxin on each cause
of death (based on cause-specific hazards). All pa-
tients were included in these models with follow-up
time censored at the last date known alive until
180 days or date of death from another mode, and
hazard ratios with associated 95% confidence in-
tervals estimated from these models are presented.
The p values from the log-rank test are presented.
Chi-square tests were used to determine differences
between cause-of-death categories in the 2 RELAX
trials and by age and ejection fraction (EF) in RELAX-
AHF-2. The Fine and Gray subdistribution hazard
competing risk model was fitted to obtain the cumu-
lative incidence function for each cause of death for
both RELAX trials. SAS release 9.4 (SAS Institute, Inc.,
Cary, North Carolina) was used for analyses.







All 367 (11.2) 388 (11.9) 755 (11.5)
CV 285 (8.7) 290 (8.9) 575 (8.8)
HF or cardiogenic shock 133 (4.1) 157 (4.8) 290 (4.4)
Sudden cardiac death 68 (2.0) 70 (2.1) 138 (2.1)
Other 84 (2.6) 63 (1.9) 147 (2.2)
Cerebrovascular accident 21 (0.6) 12 (0.4) 33 (0.5)
Acute coronary syndrome 16 (0.5) 9 (0.3) 25 (0.4)
Procedure complication 6 (0.2) 13 (0.4) 19 (0.3)
Systemic or pulmonary embolism 6 (0.2) 4 (0.1) 10 (0.1)
Peripheral arterial disease 2 (0.1) 0 (0.0) 2 (0.0)
Presumed CV/unknown 33 (1.0) 25 (0.8) 58 (0.9)
Non-CV 82 (2.5) 98 (3.0) 180 (2.8)
Infectious 29 (0.9) 31 (1.0) 60 (0.9)
Pulmonary 18 (0.6) 25 (0.8) 43 (0.7)
Malignancy 9 (0.3) 21 (0.6) 30 (0.5)
Gastrointestinal 8 (0.2) 7 (0.2) 15 (0.2)
Renal 6 (0.2) 5 (0.2) 11 (0.2)
Neurological 5 (0.2) 2 (0.1) 7 (0.1)
Other 7 (0.2) 7 (0.2) 14 (0.2)
Values are n (%). Cause of death in RELAX-AHF-2 by treatment arm with etiologies of “other” CV
and non-CV death.
CV ¼ cardiovascular; HF ¼ heart failure; RELAX-AHF-2 ¼ Efficacy, Safety and Tolerability of
Serelaxin When Added to Standard Therapy in AHF-2.
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RESULTS
Of the 6,545 patients included in the intention-to-
treat analysis of RELAX-AHF-2, 755 (11.5%) died
within 180 days. The majority of deaths were due
to CV causes (n ¼ 575; 76% of total deaths),
attributable most commonly to HF (n ¼ 290; 38% of
total deaths), followed by “other CV death”
(n ¼ 147; 20% of total deaths) and SCD (n ¼ 138;
18% of total deaths) (Figure 1). By comparison, 107
of 1,161 of patients (9.2%) in RELAX-AHF died by
180 days of follow-up. Both trials had similar
proportions of patients in the 4 categories of death
(p ¼ 0.2370). In RELAX-AHF-2, among the 147 pa-
tients classified as having “other CV death” (i.e.,
not from HF or SCD), 33 had cerebrovascular acci-
dents, 25 had acute coronary syndromes, 19 deaths
were related to CV procedures, and 58 were clas-
sified as unknown/presumed CV death (Table 1).
Overall, 180 patients (24% of total deaths; 2.8% of
the trial population) died of non-CV causes,
including 60 infection, 43 pulmonary cause
(including pneumonia), 30 malignancy, and 11 renal
failure (Table 1).













Age, yrs 72.6  11.2 76.2  10.5 76.7  10.2 73.2  12.0 75.4  10.5 78.4  9.4
Weight, kg 84.5  20.0 81.5  20.8 82.2  20.5 83.7  22.9 78.8  19.2 80.9  20.8
SBP, mm Hg* 146.4  16.8 144.4  15.8 141.8  14.4 145.9  17.2 145.3  16.8 146.9  15.4
DBP, mm Hg* 82.4  14.2 80.1  13.4 77.9  12.5 83.3  14.1 82.3  14.8 79.6  12.6
Heart rate, beats/min* 83.5  17.1 83.7  16.5 83.7  15.7 82.4  16.6 84.9  17.2 83.7  17.3
Respiratory rate, breaths/min* 21.8  4.5 22.6  5.3 22.4  4.8 23.3  5.9 22.8  5.0 22.4  5.7
Most recent EF, % 39.9  13.8 39.3  14.4 38.6  13.9 38.2  14.5 41.0  16.5 40.2  13.7
Number of admissions for HF in past year 1.1  1.2 1.3  1.2 1.4  1.3 1.1  1.0 1.2  1.1 1.2  1.2
Men 3,450 (59.6) 458 (60.7) 171 (59.0) 94 (68.1) 81 (55.1) 112 (62.2)
White 5,307 (91.7) 709 (93.9) 273 (94.1) 127 (92.0) 139 (94.6) 170 (94.4)
EF <40% 1,364/2,772 (49.2) 195/366 (53.3) 84/152 (55.3) 37/71 (52.1) 32/65 (49.2) 42/78 (53.8)
Admitted to hospital for
HF in past year
2,896/5,397 (53.7) 442/718 (61.6) 191/280 (68.2) 88/134 (65.7) 71/138 (51.4) 92/166 (55.4)
Medical history
Asthma 261 (4.5) 38 (5.0) 17 (5.9) 9 (6.5) 6 (4.1) 6 (3.3)
Blood transfusion 446 (7.7) 71 (9.4) 27 (9.3) 12 (8.7) 12 (8.2) 20 (11.1)
Bronchitis 447 (7.7) 60 (7.9) 28 (9.7) 9 (6.5) 12 (8.2) 11 (6.1)
CABG 833 (14.4) 128 (17.0) 54 (18.6) 16 (11.6) 23 (15.6) 35 (19.4)
Cardiac pacemaker insertion 727 (12.6) 115 (15.2) 46 (15.9) 7 (5.1) 16 10.9) 46 (25.6)
Cardiac resynchronization therapy 219 (3.8) 35 (4.6) 16 (5.5) 6 (4.3) 6 (4.1) 7 (3.9)
Cerebrovascular accident 870 (15.0) 138 (18.3) 51 (17.6) 27 (19.6) 25 (17.0) 35 (19.4)
Chronic obstructive pulmonary disease 891 (15.4) 150 (19.9) 60 (20.7) 22 (15.9) 27 (18.4) 41 (22.8)
Depression 544 (9.4) 79 (10.5) 31 (10.7) 12 (8.7) 14 (9.5) 22 (12.2)
Hyperlipidemia 2,955 (51.0) 356 (47.2) 135 (46.6) 63 (45.7) 72 (49.0) 86 (47.8)
Hypertension 5,191 (89.7) 684 (90.6) 263 (90.7) 121 (87.7) 136 (92.5) 164 (91.1)
Hyperthyroidism 198 (3.4) 22 (2.9) 8 (2.8) 2 (1.4) 2 (1.4) 10 (5.6)
Hypothyroidism 626 (10.8) 78 (10.3) 31 (10.7) 11 (8.0) 17 (11.6) 19 (10.6)
Implantable defibrillator insertion 508 (8.8) 68 (9.0) 26 (9.0) 15 (10.9) 12 (8.2) 15 (8.3)
Ischemic heart disease 1,875 (32.4) 269 (35.6) 116 (40.0) 49 (35.5) 53 (36.1) 51 (28.3)
Percutaneous coronary intervention 1,379 (23.8) 193 (25.6) 71 (24.5) 41 (29.7) 36 (24.5) 45 (25.0)
Peripheral arterial disease 740 (12.8) 137 (18.1) 49 (16.9) 26 (18.8) 20 (13.6) 42 (23.3)
Diabetes mellitus 2,637/5,787 (45.6) 376/755 (49.8) 150/290 (51.7) 63/138 (45.7) 78/147 (53.1) 85/180 (47.2)
eGFR (ml/min) 52  14.3 46.1  14.0 44.5  13.3 48.6  14.4 47.1  14.3 45.8  14.5












Values are mean  SD, n (%), n/N, or median (interquartile range Q1–Q3). Baseline demographics of survivors and nonsurvivors, with nonsurvivors further characterized by cause of death. *Vital signs at
screening visit.
CABG ¼ coronary artery bypass grafting; DBP ¼ diastolic blood pressure; EF ¼ ejection fraction; eGFR ¼ estimated glomerular filtration rate; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide;
SBP ¼ systolic blood pressure; other abbreviations as in Table 1.
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Baseline characteristics of survivors and non-
survivors by cause of death are outlined in Table 2.
Nonsurvivors were older, more frequently had pre-
vious hospitalization for HF in the preceding year,
and had a higher burden of comorbidities, including
history of coronary bypass surgery, cerebrovascular
accident, obstructive pulmonary disease, and pe-
ripheral arterial disease. They also had worse renal
function (lower estimated glomerular filtration rate)
and higher natriuretic peptide levels.
There was no apparent effect of treatment with
serelaxin on any category of cause of death (Figures 2
and 3, Supplemental Table 1) in RELAX-AHF-2. Pa-
tients in RELAX-AHF had a numerically higher pro-
portions of deaths in the SCD and other CV death
categories, whereas patients in RELAX-AHF-2 had a
numerically higher proportion of deaths due to non-
CV causes (Figure 1).
AGE AND CAUSE OF DEATH. The mean age of pa-
tients enrolled in RELAX-AHF-2 was approximately
73 years, and more than one-half of patients were $75
years old (n ¼ 3,302), allowing unique insight into
cause of death in older patients with AHF. To further
understand this relationship, we analyzed cause of
death in older versus younger patients (Table 3). As
expected, the age group $75 years had higher mor-
tality (n ¼ 468; 14.2% of cohort) than the younger
group of patients (n ¼ 287; 8.8% of cohort). The dis-
tribution of cause of death also differed by age group,
with more SCD seen in younger patients and more
non-CV deaths in older patients.
CAUSE OF DEATH IN HFpEF VERSUS HFrEF. RELAX-
AHF-2 enrolled a heterogeneous AHF population
across the spectrum of left ventricular EF. To better
understand how differences in EF have an impact on
cause of death after AHF, we assessed cause of death
based on preserved EF ($50%; n ¼ 1,595) versus
reduced EF (<50%; n ¼ 4,533) in patients in RELAX-
AHF-2 (Table 4) in whom EF was available at enroll-
ment (n ¼ 6,128). By 180 days of follow-up, 498 pa-
tients (11.0%) with heart failure with reduced ejection
fraction (HFrEF) died, and 183 patients (11.5%) with
HFpEF died. Patients with reduced versus preserved
EF had significantly different proportions of patients
in each category of death, with HFrEF patients having
more HF deaths (40% vs. 30%) and HFpEF patients
having more non-CV deaths (36% vs.
20%) (p < 0.0001).
DISCUSSION
Improved insight into the specific causes of death
after AHF can inform understanding of the results of
specific clinical trials and provide direction for new
therapeutic interventions. We aimed to use adjudi-
cated cause of death data from the RELAX-AHF-2
study to better understand the discrepant results of
the RELAX-AHF and RELAX-AHF-2 studies and
identify potential opportunities to better target
therapies in patients with AHF (Central Illustration).
Unlike RELAX-AHF, in which treatment with ser-
elaxin reduced 180-day all-cause and CV mortality,
primarily through reduction in “other CV deaths,”
serelaxin use did not have a significant impact on any
cause of death in RELAX-AHF-2. Multiple potential
explanations for the different results from RELAX-
AHF and RELAX-AHF-2 include differences in pa-
tient population, investigative sites, trial design, and
the play of chance. In a previously published analysis,
the reduction in stroke deaths observed in RELAX-
AHF was postulated to be due to improved blood
pressure control or favorable vascular changes, and
putative mechanisms for a marginal reduction in SCD
including reduction in ischemia or contribution of
additional pleotropic effects of serelaxin, including
anti-inflammatory, antifibrotic, and vasodilatory
properties (6). We did not confirm a treatment effect
of serelaxin on these specific causes of death in
RELAX-AHF-2, suggesting that it is unlikely that ser-
elaxin therapy conferred an important benefit with
regard to these endpoints. Despite the intention to
enroll similar patients, patients in RELAX-AHF-2 had
a 33% higher rate of non-CV death (24% vs. 18% of
total deaths) than patients in RELAX-AHF. The higher
incidence of non-CV death in RELAX-AHF-2 suggests
that these patients may have had higher non-CV (and
thus were less modifiable with a HF intervention)
competing risk than patients in RELAX-AHF.
IMPLICATIONS FOR MANAGEMENT OF AHF AND
FUTURE TRIALS. In comparison to chronic HF, the
FIGURE 2 Treatment Effects of Serelaxin by Cause of Death in Both RELAX-AHF Trials
Hazard ratios with 95% confidence intervals for serelaxin versus placebo for overall
mortality and each of the categories of cause of death. Abbreviations as in Figure 1.
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period after an AHF hospitalization is a higher risk
period, sometime termed the “vulnerable phase” (8).
In comparison to patients with chronic HF, patients
with AHF have higher short-term event rates and a
higher proportion of HF deaths versus other causes of
death (9). In RELAX-AHF-2, patients had a 180-day
mortality of 11.5% after AHF hospitalization, with a
large proportion of deaths due to HF (38%). Similarly,
causes of death in the EVEREST (Efficacy of Vaso-
pressin Antagonism in Heart Failure Outcome Study
with Tolvaptan) trial were predominantly related to
HF (41%) and SCD (26%) (10). To our knowledge, the
current analysis is the largest to date examining
adjudicated cause of death in patients after AHF
hospitalization and supports previous data indicating
that a significant portion of early deaths after AHF are
HF-related (11).
Similar to other trials of AHF, the findings observed
in RELAX-AHF-2 suggest that short-term therapies
are unlikely to have a lasting impact on long-term
mortality compared to standard of care (12,13). How-
ever, a hospitalization for AHF may be an opportune
time to initiate (or titrate) chronic guideline-directed
medical therapy, a strategy that has generated some
evidence of clinical benefit (14–17).
IMPLICATIONS FOR HF MANAGEMENT IN THE ELDERLY.
Older patients with HF tend to have a greater burden
of comorbidities and other competing risks than do
younger patients with HF. With an average age of 73
years, which is older than in many comparable AHF
FIGURE 3 Competing Risk Analysis of Both RELAX-AHF Trials
Competing risk analysis demonstrates probability of dying from each cause of death over follow-up for serelaxin and placebo arms of RELAX-AHF and RELAX-AHF-2.
Abbreviations as in Figure 1.
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studies (68 years in TRUE-HF [Efficacy and Safety of
Ularitide for the Treatment of Acute Decompensated
Heart Failure] and 67 years in ASCEND-HF [Double-
Blind, Placebo-Controlled, Multicenter Acute Study of
Clinical Effectiveness of Nesiritide in Subjects With
Decompensated Heart Failure]), the RELAX-AHF-2
program provided a unique opportunity to assess
cause of death in older patients with HF (12,13).
Compared to previous studies assessing cause of
death in AHF patients with HFrEF (13.2% at median
follow-up of 9.9 months) and across the spectrum of
EF (11.9% at 6 months), our rate of non-CV death at
180 days was higher (24%) (10,11), which may be
attributable to the more contemporary nature of and
improved standard of HF care within our trial, but
also inclusion of a more elderly population. Our study
demonstrates that older patients in RELAX-AHF-2, in
particular, had significantly higher proportions of
non-CV death compared to younger patients (27% vs.
19%) and lower relative and absolute rates of CV
death. Hospitalization for AHF may represent an op-
portunity to coordinate multimodal care for elderly
patients with additional comorbidities in order to
mitigate some non-CV deaths (18).
Younger patients had more from SCD (24% vs.
15%). A recent trial assessing the benefit of implant-
able cardioverter-defibrillators in patients with non-
ischemic cardiomyopathy with depressed EF found
that prophylactic implantable cardioverter-
defibrillator insertion in this population was not
associated with long-term reduction in mortality (19).
However, when assessed specifically by age, younger
patients with fewer comorbidities tended to derive
benefit whereas older patients with more comorbid-
ities did not (20). Although these findings are in a
different population, our analysis supports their
plausibility.
IMPLICATIONS FOR MANAGEMENT OF HFpEF. Pa-
tients with HFpEF account for a growing proportion
of patients hospitalized with AHF (21). Although
RELAX-AHF-2 enrolled mostly patients with reduced
EF (74%), those with preserved EF had a similar
incidence of 180-day mortality (11.0% vs. 11.5%) but
with significantly different proportions of patients in
each category of death. Patients with HFrEF had a
higher proportion of patients with HF death (40% vs.
30%), whereas those with HFpEF had a higher pro-
portion of patients with non-CV death (36% vs. 20%).
Our findings are in line with previous studies,
demonstrating that (1) patients have higher short-
term mortality post-AHF, regardless of EF (11); (2)
long-term mortality is similar between HFrEF and
HFpEF patients post-AHF (22); but (3) patients with
HFrEF tend to have higher rates of CV and HF read-
missions, whereas patients with HFpEF tend to have
more non-CV readmissions and non-CV death (22–24).
Within our HFpEF group, rates of non-CV death (36%)
were similar to those in the CHARM-Preserved (Can-
desartan in Heart failure Assessment of Reduction in
Mortality and Morbidity) trial (29%) (25), I-Preserve
(Irbesartan in Heart Failure With Preserved Ejection
Fraction Study) trial (30%) (26), and TOPCAT (Spi-
ronolactone for Heart Failure with Preserved Ejection
Fraction) trial (28%) (27). In the EVEREST trial, which
enrolled patients with EF #40%, non-CV death
accounted for only 13.2% of deaths during follow-up.
In totality, these findings demonstrate that patients
with both HFrEF and HFpEF have significant short-
term mortality, with a higher contribution of non-
CV causes in those with HFpEF.
Heterogeneity of the tested population is a
commonly postulated reason for failure of previous
HFpEF trials. Biopsy studies indicate that a substan-
tial proportion of these patients may have cardiac
amyloidosis (28) or represent other distinct phe-
nogroups that may have different risk profiles and






(<75 yrs vs. $75 yrs)
HF death 103 (36) 187 (40) 0.0014
SCD 70 (24) 68 (15)
Other CV death 60 (21) 87 (19)
Non-CV death 54 (19) 126 (27)
Total 287 (100) 468 (100)
Values are n (%), unless otherwise indicated. In RELAX-AHF-2, 8.8% (287 of 3,243) of patients
age <75 years and 14.2% (468 of 3,302) of patients age $75 years died. These groups had
significantly different proportions of patients in the 4 categories of cause of death, with a
higher proportion of sudden death at age <75 years and a higher proportion of non-CV death at
age $75 years. *Based on Chi-square test.
SCD ¼ sudden cardiac death; other abbreviations as in Table 1.
TABLE 4 Cause of Death by EF in RELAX-AHF-2
EF <50% (n ¼ 498) EF $50% (n ¼ 183) p Value*
HF death 200 (40) 54 (30) <0.0001
SCD 101 (20) 26 (14)
Other CV death 99 (20) 38 (21)
Non-CV death 98 (20) 65 (36)
Total 498 (100) 183 (100)
Values are n (%), unless otherwise indicated. Patients with reduced EF (<50%;
n ¼ 4,533) vs. preserved EF ($50%; n ¼ 1,595) had significantly different pro-
portions of patients in the 4 categories of cause of death. Patients with EF <50%
had a significantly higher proportion of patients with HF death, whereas those with
EF $50% had significantly higher proportion of patients with non-CV death.
*Based on Chi-square test.
Abbreviations as in Tables 1 to 3.
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responses to treatment (29–31). Patients with HFpEF
tend to have a higher burden of non-CV comorbidities
than those with HFrEF, and HFpEF phenogroups with
a high prevalence of these comorbidities tend to fare
clinically worse (24,29,30,32). Combined with evi-
dence that HFpEF patients have more non-CV hos-
pitalization and death, clinical care and future trials
should incorporate strategies focused on mitigating
these comorbidities to improve outcomes. Trials
assessing the impact of sodium glucose cotransporter
2 inhibitors (Dapagliflozin Evaluation to Improve the
LIVEs of Patients With PReserved Ejection Fraction
Heart Failure [DELIVER]; NCT03619213) and intrave-
nous iron (Effect of IV Iron in Patients With
Heart Failure With Preserved Ejection Fraction [FAIR-
HFpEF]; NCT03074591) on outcomes in HFpEF pa-
tients are ongoing. Furthermore, routine preventa-
tive care strategies—optimal control of diabetes,
recommended cancer screening, vaccine administra-
tion—all are important adjuncts to HF care and may
play a role in reducing morbidity and mortality in
these patients.
CONCLUSIONS
Our analysis of cause of death in RELAX-AHF-2 did
not identify an effect of serelaxin on any specific
cause of death in the population studied. An
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In an analysis of adjudicated cause of death in a large, contemporary, heterogeneous acute heart failure (AHF) population across the spectrum of ejection
fraction (EF), 180-day mortality was 11.5% and was primarily due to heart failure (HF) (38% of all deaths). Older patients had higher rates of death than
younger patients (14.2% vs. 8.8%) and suffered more from non cardiovascular (CV) death. Patients with preserved EF had rates of death similar to those
with reduced EF (11.5% vs. 11.0%) but also had more non-CV death. RELAX-AHF-2 ¼ Efficacy, Safety and Tolerability of Serelaxin When Added to
Standard Therapy in AHF-2.
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increased rate of non-CV death, in older patients and
in those with HFpEF in particular, may limit the
impact of CV focused therapies on mortality in this
population, highlighting the need for a multilayered
approach that optimizes chronic HF therapy and ad-
dresses both CV and non-CV morbidities for
improving long-term outcomes after AHF.
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